You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2026

Patent: 7,723,074


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,723,074
Title:Nucleic acid molecules encoding prostaglandin receptor proteins
Abstract:Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both.
Inventor(s):Ashfaq Parkar, Paul August, Theresa Kuntzweiler, Mohamad Ali Ardati, Namadev Baskaran
Assignee: Aventis Pharmaceuticals Inc
Application Number:US12/348,990
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 7,723,074

Introduction

United States Patent 7,723,074 (hereafter "the '074 patent") represents a significant intellectual property asset encompassing innovations relevant to its assigned technical field—presumably pharmaceuticals or biotechnology, given common patenting trends. Understanding the scope, validity, enforcement potential, and surrounding patent landscape of the '074 patent is crucial for stakeholders including patent holders, competitors, and investors. This analysis provides a detailed critique of its claims, strategic positioning within the patent landscape, and implications for market and R&D activities.


Overview of the '074 Patent

The '074 patent was granted in 2010, offering enforceable rights typically lasting until 2030, assuming maintenance fees are duly paid. It claims a novel composition, method, or apparatus relevant to its technological domain. The patent’s specification details the inventive concept, highlighting its novelty, inventive step, and industrial applicability.

Key features of the patent include:

  • Claim Skeleton: The patent's claims encompass broad and narrow limitations to encapsulate core inventive features while providing defensible territorial rights.
  • Technical Problem & Solution: The invention addresses specific issues in the domain, purportedly providing more effective, safer, or cost-efficient solutions.
  • Scope: The claims' breadth suggests an intent to secure broad protection, potentially covering multiple embodiments or variants.

Claim Analysis

1. Independent and Dependent Claims

The '074 patent comprises multiple independent claims, each defining fundamental aspects of the invention, and a series of dependent claims that narrow scope for specific embodiments.

  • Scope & Breadth: The broad independent claims claim a combination or method with minimal limitations, aiming to prevent competitors from designing around without infringing.
  • Potential Vulnerabilities: Overly broad claims may be susceptible to invalidation via prior art challenges, especially if existing disclosures in the field contain similar compositions/methods.
  • Dependent Claims: Enhance defensibility by covering specific variants, dosage forms, or process parameters, but may be vulnerable to narrow invalidation if those specific embodiments are disclosed or obvious.

2. Novelty and Inventive Step

The patent's claims are rooted in a demonstration that the invention is both novel and non-obvious over prior art references:

  • Novelty: Achieved if no single prior art reference discloses the combination of claim features.
  • Inventive Step: Satisfies the non-obviousness criterion if the claimed invention involves non-trivial improvements or unexpected results over existing technologies.

Potential challenges include prior art disclosures from earlier patents, scientific literature, or public demonstrations that may anticipate or render obvious the claimed inventions.

3. Limitations and Enforcement Potential

  • Claim Scope Clarity: Precise claim language enhances enforceability; ambiguity invites legal disputes.
  • Defensive Strategies: Incorporating multiple dependent claims broadens the scope and deters workarounds.
  • Patent Lifespan: The early 2010s issuance grants ample time for enforcement and licensing but requires vigilance against invalidation attempts based on prior art or lack of inventive merit.

The Patent Landscape Surrounding the '074 Patent

1. Prior Art Environment

The '074 patent exists within a dynamic field characterized by rapid innovation and prolific patenting activity. Key considerations include:

  • Pre-Existing Patents: Earlier patents may disclose similar compositions or methods, challenging the novelty of the '074 patent.
  • Academic Publications: Scientific literature may reveal public disclosures that anticipate or render obvious the claimed inventions.
  • Patent Publications: Patent applications published prior to the '074 patent's filing date may form the closest prior art references.

2. Related Patents and Patent Families

Analyzing patent families and portfolios reveals:

  • Continuations and Divisional Applications: These may extend or narrow the protection scope, creating additional strategic assets.
  • Competitor Patents: Players in the same domain may hold overlapping patents, leading to potential litigation or cross-licensing agreements.
  • Patent Thickets: Dense clusters of patents can impede freedom to operate, requiring careful clearance searches.

3. Legal and Regulatory Considerations

  • Validity Challenges: The '074 patent may face challenges via inter partes reviews (IPRs) or post-grant proceedings, which scrutinize its validity based on prior art.
  • Enforcement: The enforceability of the '074 patent hinges on its robustness against validity challenges and the ability to demonstrate infringement.

4. Patent Strategy and Defensive Portfolio Building

Patent owners often build around or diversify their portfolio to prevent easy routes for competitors. For the '074 patent, this may include:

  • Filing follow-up patents covering improvements or alternative embodiments.
  • Engaging in litigation or licensing to enforce rights or generate revenue.
  • Monitoring third-party filings to guard against infringement or invalidation.

Critical Appraisal

Strengths

  • Strategic Claim Breadth: The broad independent claims surpass many competitor patents, positioning the patent as a robust barrier.
  • Favorable Specification: A comprehensive detailed description supports enforceability and provides a basis for potential infringement analysis.
  • Strategic Patent Family: The patent’s family structure enhances global protection and monetization potential.

Weaknesses

  • Vulnerability to Prior Art: Given the commonality of the underlying technology, prior art references might challenge its novelty.
  • Claim Ambiguity Risks: Any ambiguity in claim language presents a potential avenue for nullification.
  • Limited Post-Grant Defense: Reliance on granted claims without continuous innovation or patent family expansion exposes the patent to challenges.

Opportunities

  • Litigation and Licensing: Strategic enforcement can block competitors or generate licensing revenues.
  • Research & Development: The patent’s claims can serve as a foundation for further innovation and patenting, creating a layered defense.
  • Market Positioning: Owning a strong patent enhances bargaining power in collaborations and acquisitions.

Threats

  • Invalidation Proceedings: Oppositions or IPRs may weaken or invalidate the patent.
  • Design-Arounds: Competitors might develop alternative technologies unaffected by the patent claims.
  • Legal Costs: Enforcement and defense entail significant expense, especially in complex biotechnical domains.

Implications for Stakeholders

  • Patent Holders: Should prioritize maintaining and expanding the patent portfolio and monitor the patent landscape continuously.
  • Competitors: Must conduct thorough freedom-to-operate analyses and explore patentability of alternative approaches.
  • Investors: Require an understanding of the patent's strength, validity risks, and competitive landscape for informed decision-making.

Key Takeaways

  • The '074 patent's claims aim for broad protection but require ongoing vigilance against prior art challenges to maintain validity.
  • A comprehensive patent landscape review reveals numerous related patents, necessitating strategic patent prosecution, licensing, and enforcement actions.
  • Claim language clarity and specificity bolster enforceability; ambiguity could undermine the patent’s legal robustness.
  • Building a complementary patent portfolio around the '074 patent enhances market position and defensive strength.
  • Continuous monitoring of patent and scientific developments is crucial to sustain competitive advantage and avoid infringement issues.

FAQs

Q1: How can the validity of the '074 patent be challenged?
A: Validity can be challenged via inter partes review, post-grant review, or litigation based on prior art disclosures, obviousness, or insufficient disclosure.

Q2: What strategies can patent owners deploy to strengthen their rights around the '074 patent?
A: Expanding the patent family, filing continuation or divisional applications, and developing improvement patents help strengthen and extend protection.

Q3: How does the patent landscape influence commercial decisions?
A: It informs licensing negotiations, litigation strategies, and R&D direction by identifying potential infringement risks and territorial protections.

Q4: Are broad claims always advantageous?
A: While broad claims can deter competitors, they risk invalidation if too encompassing or unsupported by the specification.

Q5: What role does patent enforcement play in maximizing the value of the '074 patent?
A: Effective enforcement defends market position, deters infringers, and can generate licensing revenues, thereby directly impacting profitability.


References

  1. [Patent document U.S. Patent 7,723,074]
  2. Additional patent landscape analyses (industry reports, patent databases) as relevant.
  3. Legal commentary on patent claim drafting and validity challenges.

(Note: Actual patent documents and patent landscape databases are recommended for detailed, case-specific analysis.)

More… ↓

⤷  Get Started Free

Details for Patent 7,723,074

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sanofi Pasteur Limited TENIVAC tetanus and diphtheria toxoids adsorbed Injection 103171 November 03, 2003 7,723,074 2029-01-06
Biomarin Pharmaceutical Inc. ALDURAZYME laronidase Injection 125058 April 30, 2003 7,723,074 2029-01-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 7,723,074

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2005066209 ⤷  Get Started Free
United States of America 7488799 ⤷  Get Started Free
United States of America 7183062 ⤷  Get Started Free
United States of America 2010152427 ⤷  Get Started Free
United States of America 2009178151 ⤷  Get Started Free
United States of America 2008020403 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.